Just-Evotec Biologics Selected by U.S. DOD for Manufacturing Optimization

Just – Evotec Biologics, a subsidiary of Evotec SE, has been selected by the U.S. Department of Defense for the Manufacturing Optimization Program. The multi-year contract, valued up to $39 million, aims to enhance the rapid response capabilities of the U.S. Government for biologics medical countermeasures (MCMs).

The program focuses on accelerating monoclonal antibody development and manufacturing. Just – Evotec Biologics will work on technologies and processes to decrease development and manufacturing timelines while maintaining high quality and safety standards. The ultimate goal is to achieve a 100-day timeline from pathogen identification to the production of clinical doses.

Dr. Linda Zuckerman, Executive Vice President of Biotherapeutics at Just – Evotec Biologics, expressed pride in contributing to this program. Dr. Matthias Evers, Chief Business Officer of Evotec, emphasized the strategic importance of this program in advancing innovation in monoclonal antibody development and manufacturing.